A daily newsletter read by 2,700+ industry professionals — covering the deals, trials, approvals, and funding that are shaping the industry.
TLDR Biotech is a free daily newsletter written by the team at Science 2 Sales. Every weekday morning (PST), it delivers the most important stories from the biotech and pharma world - written to be skimmable for people who work in the space.
From billion-dollar M&A deals to clinical readouts, regulatory approvals to funding rounds, TLDR Biotech keeps you informed without the noise.
Trusted by scientists, BD professionals, founders, investors, and sales teams across the biotech & pharma ecosystem.
Each issue surfaces the most relevant stories across the full biotech and pharma landscape.
Acquisitions, licensing agreements, and strategic partnerships across biotech and pharma.
Phase 1, 2, and 3 readouts — the data that moves markets and shapes pipelines.
FDA and EMA decisions, breakthrough designations, and accelerated approvals.
Seed to IPO — who raised, how much, and what they're building with it.
Capacity expansions, supply chain shifts, and new facility investments.
Emerging modalities, platform technologies, and research breakthroughs.
TLDR Biotech is built by Science 2 Sales, and helps us and our clients build aware inside the biotech and pharma ecosystem before ever sending a single piece of outreach.
When your outbound comes from a recognized name in the industry, prospects respond differently. Getting your product or service in-front of our audience is a key part of our outreach.
Put your brand directly in front of 2,700+ life sciences professionals who are already paying attention to the space.
Prospects recognize TLDR Biotech, so advertising your product/service in the newsletters makes our outreach feel warm even when it's cold.
Publishing daily keeps us on the pulse of deals, funding, and company movements - intelligence that sharpens every campaign.
Join 2,700+ biotech and pharma professionals. Free, daily, and straight to the point.